ストックスクリーナーアプリを入手
30.47
0.59%
-0.18
アフターアワーズ：
30.47
前日終値:
$30.65
開ける：
$29.99
24時間の取引高:
2.15M
Relative Volume:
0.89
時価総額：
$3.71B
収益：
$1.24B
当期純損益:
$209.00M
株価収益率:
18.35
EPS:
1.6605
ネットキャッシュフロー:
$-94.86M
1週間 パフォーマンス:
+1.74%
1か月 パフォーマンス:
-4.72%
6か月 パフォーマンス:
+31.00%
1年 パフォーマンス:
+220.06%
1日の値動き範囲:
$29.65
$30.57
1週間の範囲:
$28.66
$31.25
52週間の値動き範囲:
$8.64
$38.00
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
名前
Indivior Pharmaceuticals Inc
セクター
電話
804-379-1090
住所
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
30.47 | 3.71B | 1.24B | 209.00M | -94.86M | 1.6605 |
TAK
Takeda Pharmaceutical Co Adr
|
18.74 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
117.94 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.93 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.08 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
564.81 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-07-22 | 再開されました | Jefferies | Buy |
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2024-07-23 | 開始されました | Piper Sandler | Overweight |
| 2024-04-03 | 開始されました | Craig Hallum | Buy |
| 2023-07-13 | 開始されました | Northland Capital | Outperform |
すべてを表示
Indivior Pharmaceuticals Inc (INDV) 最新ニュース
INDV Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Indivior Pharmaceuticals Inc. R (E7P.F) Insider Ownership & Holdings - Yahoo! Finance Canada
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B - MSN
JPMorgan Chase & Co. Has $5.01 Million Holdings in Indivior PLC $INDV - MarketBeat
Did Potential Jail Staffing Efficiencies From SUBLOCADE® Just Shift Indivior Pharmaceuticals' (INDV) Investment Narrative? - Sahm
Indivior Pharmaceuticals Inc. R (E7P.F) Valuation Measures & Financial Statistics - Yahoo! Finance Canada
Down 12.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Indivior Pharmaceuticals Inc. (INDV) - MSN
INDV Technical Analysis & Stock Price Forecast - Intellectia AI
Indivior Pharmaceuticals, Inc. (INDV) Stock forecasts - uk.finance.yahoo.com
What Indivior Pharmaceuticals (INDV)'s Prison Cost Model Findings Mean For Shareholders - finance.yahoo.com
Indivior Pharmaceuticals, Inc. (INDV) Stock Forecasts - Yahoo Finance
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD - The Globe and Mail
Indivior Pharmaceuticals, Inc - Reuters
Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND - TradingView
New Cost Impact Model Highlights Potential Benefits of Monthly Injectable Buprenorphine - National Today
New Cost Model Shows Monthly Injectable Buprenorphine Can Reduce Staffing Burdens in Prisons - National Today
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities - The Manila Times
Monthly opioid addiction shot may cut jail staffing, model estimates - Stock Titan
Zacks.com spotlights Indivior, Ciena, and Ultra Clean as notable mentions - Bitget
Zacks.com featured highlights include Indivior, Ciena and Ultra Clean - Yahoo Finance
FOCUS-Drugmakers delay some European launches with a wary eye on Trump's pricing policies - Sahm
Indivior PLC (NASDAQ:INDV) Short Interest Up 21.7% in March - MarketBeat
Indivior: Still Attractive After FY25 Earnings Beat (NASDAQ:INDV) - Seeking Alpha
Is It Time To Reassess Indivior Pharmaceuticals (INDV) After Its 200% One Year Surge? - simplywall.st
Hennion & Walsh Asset Management Inc. Purchases 96,177 Shares of Indivior PLC $INDV - MarketBeat
If You Invested $1,000 in Indivior Pharmaceuticals Inc. (INDV) - Stock Titan
SG Americas Securities LLC Buys 363,829 Shares of Indivior PLC $INDV - MarketBeat
Indivior PLC (NASDAQ:INDV) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Levi & Korsinsky Reminds Indivior Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 1, 2024INDV - MarketScreener
Indivior (INDV) posts 2025 growth, SUBLOCADE gains and $400M buyback in 2026 proxy - Stock Titan
Suboxone Market Size Forecasts 2026-2033: Analyzing Industry - openPR.com
Indivior PLC Stock Faces Uncertainty Amid U.S. Domicile Shift and OUD Market Focus - AD HOC NEWS
Indivior Pharmaceuticals Inc (INDV) Shares Up 5.07% on Mar 25 - GuruFocus
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B (XLV:NYSEARCA) - Seeking Alpha
Down 12.9% Over the Past Month: Reasons to Consider Purchasing Indivior Pharmaceuticals Inc. (INDV) During the Decline - Bitget
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug - TradingView
[SCHEDULE 13G] Indivior Pharmaceuticals, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Indivior Pharmaceuticals to report Q4 earnings: What's in the cards? - MSN
A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Recent Share Price Weakness - Sahm
Implied volatility surging for Indivior Pharmaceuticals stock options - MSN
Indivior Pharmaceuticals Inc (INDV) Shares Gap Down to $29.44 on Mar 20 - GuruFocus
Indivior (NASDAQ:INDV) Upgraded by Zacks Research to "Strong-Buy" Rating - MarketBeat
Goldentree Asset Management LP Makes New Investment in Indivior PLC $INDV - MarketBeat
Indivior outlines 30% adjusted EBITDA growth target for 2026 with new $400M share repurchase program - MSN
Indivior Issues $500 Million Convertible Senior Notes Offering - TipRanks
[Form 4] Indivior Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Indivior Pharmaceuticals Raises $500 Million Via 0.625% Convertible Notes Due 2031 - TradingView
Indivior Pharmaceuticals Survey Reveals Gaps in Medications for Opioid Use Disorder in U.S. Jails and Prisons - Quiver Quantitative
National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder - GlobeNewswire
Indivior Pharmaceuticals Inc (INDV) 財務データ
収益
当期純利益
現金流量
EPS
1.11%
大文字化:
|
ボリューム (24 時間):